Abstract
Objective: To estimate the prevalence of signs and symptoms of anxiety and depression and to assess the quality of life of patients undergoing cancer treatment. Methods: The respective study is a cross-sectional study, including 246 patients who are undergoing cancer follow-up. A questionnaire with sociodemographic variables and clinical information was used, plus the instruments: Hospital Scale for Depression and Anxiety (HADS) and World Health Organization Quality of Life (WHOQOL-bref). Results: The prevalence of moderate to severe anxiety was 33.7% (95% CI: 27.8 - 39.7) and 13.4% (95% CI: 9.1 - 17.7) for moderate depression severe. Quality of life had an average score of 68.52 points. Patients, who presented symptoms of anxiety and moderate to severe depression, had a worse assessment of quality of life in all domains. Conclusion: The significant prevalence of signs and symptoms of anxiety and depression in patients undergoing cancer has repercussions with impaired quality of life.